-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compile | newborn
Recently, the GlaxoSmithKline PD-1 inhibitor Jemperli (dostarlimab) received conditional approval from the Medicines and Healthcare Products Administration (MHRA) for the treatment of recurrent or advanced endometrial cancer
.
Jemperli is a PD-1 blocking antibody, specifically suitable for: recurrence of disease progression, mismatch repair defect (dMMR)/high degree of microsatellite instability (MSI-H) during or after treatment with platinum-containing chemotherapy Patients with sexual or advanced endometrial cancer
This approval is based on the positive results of the open-label, single-group, multi-cohort Phase 1/2 GARNET study (NCT02715284)
.
In this study, the A1 cohort enrolled patients with dMMR/MSI-H recurrence or advanced endometrial cancer who had progressed during or after treatment with platinum-containing chemotherapy
Dr.
Rebecca Kristeleit, oncology consultant for the Gay and St.
Thomas NHS Foundation Trust (GSTT) in the United Kingdom, said: "The approval of Jemperli by the British regulatory agency has added an important new option for female patients with difficult-to-treat endometrial cancer
.
dMMR/MSI-H patients with advanced or recurrent endometrial cancer have limited treatment options and poor prognosis
Currently, GlaxoSmithKline is also conducting other registration studies to evaluate Jemperli as a monotherapy and as part of a combination therapy for the treatment of patients with relapsed or primary advanced endometrial cancer and patients with non-mucinous epithelial ovarian cancer
.
Jemperli belongs to the PD-(L)1 inhibitor family, which is a type of tumor immunotherapy, which aims to use the body's own immune system to fight tumors
.
Up to now, more than 10 PD-1(L)1 inhibitors have been approved for marketing, the leader of which is Merck’s Keytruda
But among these drugs, Jemperli is the first PD-(L)1 inhibitor to obtain regulatory approval for the treatment of endometrial cancer
.
At present, Merck and Eisai's Keytruda and Lenvima combination drug program is under review by regulatory agencies
Reference source: GSK's PD-1 inhibitor Jemperli approved in the UK
